ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 983,03
0,57%
Dow Jones
38 807,33
0,25%
DAX
18 575,94
0,86%
Brent Oil
78,695
0,17%
Bitcoin
71 093,53
0,02%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Astria Therapeutics Inc (ATXS)

  7. Astria Therapeutics Inc (ATXS) Actualités

ATXS

Astria Therapeutics (ATXS)

Astria Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ATXS
DateHeureSourceTitreSymboleSociété
04/06/202422h10Business WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATXSAstria Therapeutics Inc
30/05/202414h00Business WireAstria Therapeutics to Present at Upcoming Jefferies Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
24/05/202414h00Business WireAstria Therapeutics to Present at Upcoming Eastern Allergy ConferenceNASDAQ:ATXSAstria Therapeutics Inc
23/05/202414h00Business WireAstria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology CongressNASDAQ:ATXSAstria Therapeutics Inc
09/05/202422h10Business WireAstria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
09/05/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATXSAstria Therapeutics Inc
08/05/202414h00Business WireAstria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual MeetingNASDAQ:ATXSAstria Therapeutics Inc
09/04/202414h00Business WireAstria Therapeutics Appoints Sunil Agarwal to Its Board of DirectorsNASDAQ:ATXSAstria Therapeutics Inc
25/03/202412h30Business WireAstria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAENASDAQ:ATXSAstria Therapeutics Inc
04/03/202423h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXSAstria Therapeutics Inc
04/03/202423h20Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATXSAstria Therapeutics Inc
04/03/202422h10Business WireAstria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
04/03/202422h02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ATXSAstria Therapeutics Inc
20/02/202414h00Business WireAstria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual MeetingNASDAQ:ATXSAstria Therapeutics Inc
14/02/202421h48Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ATXSAstria Therapeutics Inc
12/02/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXSAstria Therapeutics Inc
06/02/202414h00Business WireAstria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ATXSAstria Therapeutics Inc
30/01/202415h08Business WireAstria Therapeutics Announces Pricing of $125 Million Underwritten OfferingNASDAQ:ATXSAstria Therapeutics Inc
29/01/202422h39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATXSAstria Therapeutics Inc
16/01/202422h18Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ATXSAstria Therapeutics Inc
02/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATXSAstria Therapeutics Inc
28/12/202320h09Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ATXSAstria Therapeutics Inc
15/12/202314h30Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATXSAstria Therapeutics Inc
27/11/202314h00Business WireAstria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy CongressNASDAQ:ATXSAstria Therapeutics Inc
21/11/202314h00Business WireAstria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ATXSAstria Therapeutics Inc
13/11/202314h00Business WireAstria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate UpdateNASDAQ:ATXSAstria Therapeutics Inc
10/11/202314h00Business WireAstria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific MeetingNASDAQ:ATXSAstria Therapeutics Inc
09/11/202314h00Business WireAstria Therapeutics to Present at Upcoming Jefferies London Healthcare ConferenceNASDAQ:ATXSAstria Therapeutics Inc
03/11/202313h10Business WireAstria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific MeetingNASDAQ:ATXSAstria Therapeutics Inc
30/10/202313h00Business WireAstria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13thNASDAQ:ATXSAstria Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATXS

Dernières Valeurs Consultées

COIN
BRXETH
ASX
TAPR
BIT
PTR
Pattern S.p.a
NYSE
GNV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés